Avoid hiqh-dose simvastatin

July 2011
Internal Medicine Alert;7/15/2011 Pharmacology Watch, p1
The article reports on the advice given by the U.S. Food and Drug Administration (FDA) to physicians pertaining to the avoidance of prescribing high-dose simvastatin (Zocor) due to the potential risk of myopathy and rhabdomyolysis.


Related Articles

  • TAKE TWO AND CROSS YOUR FINGERS. Gifford, Bill; McClintock, Brian // Men's Health;Sep2006, Vol. 21 Issue 7, p144 

    In this report, the authors discuss the use of prescription drugs by men in the U.S. The authors cite a number of situations showing the consequences of taking prescription drugs. They state the side effects of some drugs such as Neurontin. In addition, the author reports on the drug policy...

  • Adverse Drug Event Monitoring at the Food and Drug Administration. Ahmad, Syed Rizwanuddin // JGIM: Journal of General Internal Medicine;Jan2003, Vol. 18 Issue 1, p57 

    The Food and Drug Administration (FDA) is responsible not only for approving drugs but also for monitoring their safety after they reach the market. The complete adverse event profile of a drug is not known at the time of approval because of the small sample size, short duration, and limited...

  • Doctors, consumers and adverse reactions. Levin, Arthur Aaron // HealthFacts;Aug94, Vol. 19 Issue 183, p2 

    Reports on the reports generated by medWatch, a new Food and Drug Administration (FDA) program to encourage doctors to voluntarily report adverse effects caused by drugs and devices. Effects defined as serious; Monitoring of drugs and devices after approval as the weakest link in FDA's oversight...

  • America's real drug problem.  // HealthFacts;Jun98, Vol. 23 Issue 6, p4 

    Reports on the increasing number of fatalities associated with prescription drugs in the United States. Emergence of adverse drug reactions (ADRs) as fourth leading cause of death in the U.S.; US Food & Drug Administration's (FDA) limited resources in monitoring drug safety; Reliance of FDA on...

  • Drug- and Herb-Induced Liver Failure: A Rare Adverse Reaction to a Wide Range of Medications. Napoli, Maryann // HealthFacts;Sep2001, Vol. 26 Issue 9, p2 

    Presents information on the actions taken by the Food and Drug Administration regarding reports on drug- and herb-induced liver injury in 2001.

  • Sorbitol Loser.  // Nutrition Action Health Letter;Oct99, Vol. 26 Issue 8, p2 

    Suggests that any food with at least one gram of sorbitol should carry an informative warning. Information on the sugar alcohol sorbitol; Requirement of the United States Food and Drug Administration for food warning on sorbitol.

  • New warnings on Hismanal added by FDA.  // Drug Topics;2/16/98, Vol. 124 Issue 4, p8 

    Reports that the United States Food and Drug Administration has issued warnings on life-threatening reactions to Hismanal (astemizole) used with other drugs. Identification of drugs with which the products should not be used.

  • FDA requests voluntary recall of gamma-butyrolactone. Maudlin, Robert K. // Modern Medicine;Jan2000, Vol. 68 Issue 1, p58 

    Reports that adverse effects associated with gamma-butyrolactone (GBL) have led to the United States Food and Drug Administration's request for the recall of the dietary supplement. Brand names assumed by GBL-containing products in the market; Benefits claimed by GBL-containing products;...

  • FDA WARNING FOR BISPHOSPHONATES.  // Radiology Today;Nov2010, Vol. 11 Issue 11, p37 

    The article reports on the U.S. Food & Drug Administration's (FDA) warnings about the risk of bone-strengthening drugs, bisphosphonates. The American Society for Bone and Mineral Research (ASBMR) has assembled a special task force to make recommendations submitted to the FDA associating atypical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics